Cellular Immunotherapies and Immune Modulation in Hematologic Cancers
A Special Issue of Cells (ISSN 2073-4409) belonging to the section "Cellular Immunology".
Deadline for manuscript submissions: 18 February 2027 | Viewed by 1338
Editors
Interests: cellular immunotherapy; CAR T cells; immunohematology
Special Issue Information
Dear Colleagues,
Work in cellular immunotherapy for hematologic malignancies has moved quickly, though the pace has not always clarified the underlying biology. What has become increasingly apparent is that the behavior of these therapies is shaped as much by the immune setting in which they are deployed as by the properties of the cells themselves. Across T, NK, and myeloid approaches—along with early allogeneic and combination efforts—recurring themes keep resurfacing: inflammatory responses that drift beyond expectation, metabolic limits that appear at awkward points in treatment, and microenvironmental pressures that differ more between diseases than early models suggested.
The aim of this Special Issue is to bring together work that helps make sense of these patterns rather than simply adding to the catalog of observations. Studies that clarify mechanisms, unsettle comfortable assumptions, or offer practical ways of adjusting immune behavior in favor of more durable responses are particularly relevant. The intention is to create a space where the next steps for cellular therapies in hematologic cancers can be considered with a bit more precision and, ideally, fewer illusions.
Dr. Erden Atilla
Dr. Ali Turan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cellular immunotherapy
- CAR T
- CAR NK
- immune modulation
- hematologic malignancies
- microenvironment
- cytokine biology
- immune escape
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
